Leveraged Commentary and Data’s (LCD) credit data, news, and research are now on PitchBook.
Learn more »
BSIM Therapeutics Overview
Latest Deal Type
Latest Deal Amount
BSIM Therapeutics General Information
Operator of a biotechnology company intended to fight neurodegenerative amyloid diseases. The company focuses on the design of organ-targeted, quality drug candidates for the treatment of transthyretin-mediated amyloidosis, enabling patients to improve their lives through innovative therapeutic approaches.